2,078 Eli Lilly and Company $LLY Shares Sold by AMI Asset Management Corp

Key Points

• AMI Asset Management reduced its Eli Lilly stake by 3.5%, selling 2,078 shares and retaining 56,648 shares valued at approximately $65.5 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with EPS of $8.38 versus the $6.40 consensus and revenue of $22.97 billion, up 47.7% year over year. Shares opened at $1,271.89, near their 52-week high, giving the company a market capitalization of about $1.20 trillion.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $1,317.93 price target, though pricing pressure, Novo Nordisk competition and Lilly’s premium valuation remain key risks for investors.

AMI Asset Management Corp decreased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,648 shares of the company's stock after selling 2,078 shares during the quarter. Eli Lilly and Company makes up about 3.8% of AMI Asset Management Corp's holdings, making the stock its 9th biggest position. AMI Asset Management Corp's holdings in Eli Lilly and Company were worth $65,546,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Maseco LLP grew its holdings in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after acquiring an additional 28 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. grew its stake in Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after purchasing an additional 15 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter valued at about $42,000. Caitlin John LLC purchased a new position in Eli Lilly and Company in the second quarter valued at about $64,000. Finally, IMG Wealth Management Inc. increased its position in Eli Lilly and Company by 500.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock worth $72,000 after purchasing an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,271.89 on Thursday. The stock has a market capitalization of $1.20 trillion, a P/E ratio of 42.68, a P/E/G ratio of 1.71 and a beta of 0.46. The business has a 50-day moving average of $1,182.84 and a two-hundred day moving average of $1,116.53. Eli Lilly and Company has a fifty-two week low of $793.82 and a fifty-two week high of $1,311.75. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. During the same quarter in the prior year, the firm posted $6.31 EPS. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 33.56 EPS for the current fiscal year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst target and expected earnings strength: Goldman Sachs raised its price target to $1,413 from $1,371 while maintaining a Buy rating. The firm reportedly expects Eli Lilly to beat third-quarter estimates and raise its outlook, supported by international Mounjaro growth and Zepbound volume gains. Goldman Sachs raises Eli Lilly price target
• Positive Sentiment: International manufacturing expansion: Eli Lilly signed Abu Dhabi agreements involving local packaging and advanced pharmaceutical contract manufacturing for weight-loss medicines. The company also entered a drug-delivery partnership with China’s Metis TechBio valued at up to $1.1 billion, potentially strengthening supply capacity and product-delivery capabilities. Eli Lilly Abu Dhabi packaging deal
• Positive Sentiment: Pipeline expansion: One-year Phase 3 SHINE-2 data showed Omvoh sustained clinical-remission benefits in children with ulcerative colitis, including patients who had previously failed biologic treatments. Regulatory approval could expand Lilly’s inflammatory bowel disease franchise. Pediatric ulcerative colitis data
• Neutral Sentiment: Strong growth, but pricing is a key upcoming issue: Second-quarter revenue increased 48% to approximately $23 billion as medicine volume rose 60%, while realized price per unit declined 13%. Investors will focus on whether continued demand and volume growth can offset pricing pressure when third-quarter results are released on October 29. Eli Lilly volume and pricing analysis
• Negative Sentiment: Competition and valuation risks: Novo Nordisk’s CagriSema produced 25% weight loss in women, reinforcing competitive pressure in the obesity-treatment market. After a substantial rally and record valuation, investors may also be taking profits or demanding stronger evidence that Lilly’s growth can justify its premium multiple. Novo Nordisk CagriSema results

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. BMO Capital Markets reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Bank of America lifted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a report on Friday, July 10th. Royal Bank Of Canada reissued an "outperform" rating and issued a $1,500.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 12th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a research note on Monday, September 28th. Finally, Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the stock a "buy" rating in a report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,317.93.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.